Volume 10 Issue 4
Jul.  2019
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2019  >  10(4): 449-452
Zheng Yonggen, Zhou Lin, Du Guosheng, et al. Therapeutic experience of tacrolimus-induced pain syndrome of bilateral lower limbs after liver transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(4): 449-452. doi: 10.3969/j.issn.1674-7445.2019.04.017
Citation: Zheng Yonggen, Zhou Lin, Du Guosheng, et al. Therapeutic experience of tacrolimus-induced pain syndrome of bilateral lower limbs after liver transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(4): 449-452. doi: 10.3969/j.issn.1674-7445.2019.04.017
shu

Therapeutic experience of tacrolimus-induced pain syndrome of bilateral lower limbs after liver transplantation

doi: 10.3969/j.issn.1674-7445.2019.04.017

  • Medical School of Chinese People's Liberation Army, Beijing 100091, China

More Information
  • Corresponding author: Du Guosheng, Email:duguosheng309@126.com
  • Received Date: 2019-04-03
    Available Online: 2021-01-19
  • Publish Date: 2019-07-15
    Abstract
  •   Objective  To summarize the therapeutic experience of lower limb pain syndrome caused by tacrolimus (FK506) after liver transplantation.  Methods  A 52-year-old male patient diagnosed with virus B hepatitis (hepatitis B), post-hepatitis liver cirrhosis at the decompensation stage and malignant liver tumors developed bilateral lower limbs pain syndrome after liver transplantation with FK506 immunosuppressant. After eliminating the possibility of angioneurotic pain, FK506 was terminated and replaced by sirolimus (SRL) therapy. The blood concentration was maintained at 6~8 ng/mLduring the early stage, and then gradually adjusted according to the survival time of the liver graft.  Results  After 2-weeks conversion therapy, the swelling and pain of bilateral lower limbs of the patient were gradually relieved, and the skin pruritus was gradually healed. After 1 month, the patient was basically restored to normal activity and function. No recurrence was reported until the submission date of this manuscript.  Conclusions  Bilateral lower limbs pain syndrome caused by adverse reaction of FK506 is relatively rare. FK506 can be substituted by SRL to avoid the adverse reaction.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    ALESSIANI M, CILLO U, FUNG JJ, et al. Adverse effects of FK506 overdosage after liver transplantation[J]. Transplant Proc, 1993, 25(1 Pt 1):628-634. http://cn.bing.com/academic/profile?id=db20cda4dc0e5b32407e6a2dfd91246c&encoded=0&v=paper_preview&mkt=zh-cn
    [2]
    ALSINA AE. Liver transplantation for hepatocellular carcinoma[J]. Cancer Control, 2010, 17(2):83-86. doi: 10.1177/107327481001700203
    [3]
    ZHOU L, PAN LC, ZHENG YG, et al. Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: a single center experience[J]. Oncol Lett, 2018, 16(4):4407-4417. DOI: 10.3892/ol.2018.9226.
    [4]
    周林, 郑永根, 杜国盛, 等.肝癌肝移植术后西罗莫司转换治疗的免疫学效应分析[J].解放军医药杂志, 2017, 29(4):24-28.DOI: 10.3969/j.issn.2095-140X.2017.04.007.

    ZHOU L, ZHENG YG, DU GS, et al. Immunological effect of sirolimus conversion herapy on hepatic carcinoma after liver transplantation[J]. Med Pharm J Chin PLA, 2017, 29(4):24-28. DOI: 10.3969/j.issn.2095-140X.2017.04.007.
    [5]
    MUELLER AR, PLATZ KP, BECHSTEIN WO, et al. Neurotoxicity after orthotopic liver transplantation. a comparison between cyclosporine and FK506[J].Transplantation, 1994, 58(2):155-170. doi: 10.1097/00007890-199405820-00006
    [6]
    HENDRICKSON RJ, SUJKA J, FISCHER R, et al. Indications and efficacy of conversion from tacrolimus- to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma[J].Pediatr Transplant, 2019:e13369. DOI: 10.1111/petr.13369.
    [7]
    RAYAR M, BARDOU-JACQUET E. Recurrence of primary biliary cholangitis after liver transplantation: is tacrolimus really worse than other drugs?[J].Gastroenterology, 2019, 156(8)2354. DOI: 10.1053/j.gastro.2019.02.047.
    [8]
    LEE EC, KIM SH, PARK SJ. Safety and efficacy of once-daily prolonged-release tacrolimus in living donor liver transplantation: an open-label, prospective, single-arm, phase 4 study[J]. Ann Transplant, 2018, 23:713-720. DOI: 10.12659/AOT.910618.
    [9]
    杜国盛, 周林, 石炳毅, 等.三联抗肿瘤疗法预防晚期原发性肝癌肝移植术后肿瘤复发的临床研究[J].器官移植, 2014, 5(2):74-78.DOI: 10.3969/j.issn.1674-7445.2014.02.004.

    DU GS, ZHOU L, SHI BY, et al. Clinical study of triple anti-tumor therapy for preventing tumor recurrence of terminal primary liver cancer after liver transplantation[J]. Organ Transplant, 2014, 5(2):74-78.DOI: 10.3969/j.issn.1674-7445.2014.02.004.
    [10]
    魏淑贞, 张德奎, 姜山, 等.肝移植术后服用他克莫司致神经毒性反应的观察[J].中国现代医学杂志, 2004, 14(6):90-91.DOI: 10.3969/j.issn.1005-8982.2004.06.032.

    WEI SZ, ZHANG DK, JIANG S, et al. Study on neurotoxicity of FK506 after liver transplantation[J]. Chin J Mod Med, 2004, 14(6):90-91. DOI: 10.3969/j.issn.1005-8982.2004.06.032.
    [11]
    LUÉ A, MARTINEZ E, NAVARRO M, et al. Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation[J]. Transplantation, 2019. DOI: 10.1097/TP.0000000000002750 [Epubahead of print].
    [12]
    邬蓉, 陈万生, 金晓玲, 等.原位肝移植术后患者早期神经毒性反应与他克莫司血药浓度的关系[J].第二军医大学学报, 2007, 28(12):1381-1382.DOI: 10.3321/j.issn:0258-879x.2007.12.025.

    WU R, CHEN WS, JIN XL, et al. Relationship between blood concentration of tacrolimus and neurotoxic reactions in early phase after orthotopic liver transplantation[J]. Acad J Sec Mil Med Univ, 2007, 28(12):1381-1382. DOI: 10.3321/j.issn:0258-879x.2007.12.025.
    [13]
    朱静楠, 张翠欣.肝移植受者他克莫司治疗窗浓度的初步探讨[J].临床合理用药杂志, 2012, 5(26):15-16. DOI: 10.3969/j.issn.1674-3296.2012.26.011.

    ZHU JN, ZHANG CX. Preliminary research of the therapeutic window concentration of tacrolimus in liver transplant recipients[J]. Chin J Clin Rational Drug Use, 2012, 5(26):15-16.DOI: 10.3969/j.issn.1674-3296.2012.26.011.
    [14]
    张骊, 田大治, 滕大洪, 等.肝移植术后肾功能不全病例分享[J/CD].实用器官移植电子杂志, 2017, 5(4):283-284. DOI: 10.3969/j.issn.2095-5332.2017.04.011.

    ZHANG L, TIAN DZ, TENG DH, et al. Case-sharing of renal dysfunction after liver transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2017, 5(4):283-284. DOI: 10.3969/j.issn.2095-5332.2017.04.011.
    [15]
    杜国盛, 周林, 朱志东, 等. Foxp3+调节性T细胞与肝癌肝移植患者术后肿瘤复发关系的研究[J].器官移植, 2015, 6(5):311-315.DOI: 10.3969/j.issn.1674-7445.2015.05.007.

    DU GS, ZHOU L, ZHU ZD, et al. Research on the relationship between Foxp3+ regulatory T cell and umor recurrence of patients after liver transplantation for hepatocellular carcinoma[J]. Organ Transplant, 2015, 6(5):311-315. DOI: 10.3969/j.issn.1674-7445.2015.05.007.
    [16]
    周林, 杜国盛, 朱志东, 等.预防晚期肝内胆管细胞癌肝移植术后复发的三联疗法疗效报道[J/CD].中华普外科手术学杂志(电子版), 2014, 8(1):40-43. DOI: 10.3877/cma.j.issn.1674-3946.2014.01.013.

    ZHOU L, DU GS, ZHU ZD, et al. Prevention of recurrence of end-stage intrahepatic cholangiocellular carcinoma after liver transplantation by triple therapy[J/CD]. Chin J Oper Proced Gen Sur (Electr Vers), 2014, 8(1):40-43.DOI: 10.3877/cma.j.issn.1674-3946.2014.01.013.
    [17]
    周林, 索龙龙, 宋继勇, 等.以西罗莫司为基础三联抗肿瘤疗法对大鼠肝癌肝移植复发模型T淋巴细胞的影响[J].器官移植, 2014, 5(6):368-373.DOI: 10.3969/j.issn.1674-7445.2014.06.009.

    ZHOU L, SUO LL, SONG JY, et al. Influence of sirolimus based triple anti-tumor therapy on T lymphocyte of rat model with liver cancer recurrence after transplantation[J]. Organ Transplant, 2014, 5(6):368-373. DOI: 10.3969/j.issn.1674-7445.2014.06.009.
    [18]
    MORENO GONZALES M, MYHRE L, TANER T. Sublingual tacrolimus in liver transplantation: a valid option?[J]. Transplant Proc, 2016, 48(6):2102-2106. DOI: 10.1016/j.transproceed.2016.03.043.
    [19]
    ALTIERI M, DELAVAL G, KIMMOUN E, et al. Conversion from once-daily prolonged-release tacrolimus to once-daily extended-release tacrolimus in stable liver transplant recipients[J]. Exp Clin Transplant, 2018, 16(3):321-325. DOI: 10.6002/ect.2016.0328.
    [20]
    BILBAO I, DOPAZO C, CASTELLS L, et al. Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity[J]. Transplant Proc, 2014, 46(9):3104-3107. DOI: 10.1016/j.transproceed.2014.10.001.
    [21]
    TÖNSHOFF B, HÖCKER B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity[J]. Pediatr Transplant, 2006, 10(6):721-729. DOI: 10.1111/j.1399-3046.2006.00577.x.
    [22]
    HE MK, LE Y, ZHANG YF, et al. Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma[J]. Oncol Lett, 2018, 16(1):475-482. DOI: 10.3892/ol.2018.8642.
    [23]
    LEISKAU C, RAJANAYAGAM J, PFISTER ED, et al. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation:a single center matched cohort study[J]. Pediatr Transplant, 2018, 22(5):e13207. DOI: 10.1111/petr.13207.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (313) PDF downloads(9) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return